
到 2028 年的欧洲临床试验市场预测 - 区域分析 - 按研究设计(介入性、观察性和扩大访问)、阶段(第一阶段、第二阶段、第三阶段和第四阶段)和适应症(自身免疫/炎症、疼痛管理、肿瘤学、中枢神经系统疾病、糖尿病、肥胖、心血管等)
No. of Pages: 148 | Report Code: BMIRE00028989 | Category: Life Sciences
No. of Pages: 148 | Report Code: BMIRE00028989 | Category: Life Sciences
临床试验有助于确定新的治疗或预防形式(例如新药、饮食或医疗设备)是否安全有效。试验主要在药物开发过程中进行。据欧洲药品管理局统计,欧盟(EU)每年授权约4,000项临床试验,其中约60%的临床试验与制药行业相关。由于慢性病患病率的上升,越来越多的临床试验用于开发不同的有效治疗方法,推动了临床试验市场的增长。
此外,临床试验日益变得越来越重要程序复杂,因此对研究型组织的运作进行适当的执行和监督变得至关重要。为了避免因执行不当而出现错误,研究型组织正在外包临床试验来开发其产品。临床研究组织 (CRO) 通过使用高质量设施和深厚的主题专业知识提供的服务,协助成功实施临床试验。 CRO 已开始通过其高效且具有成本效益的运营使试验申办者受益,成为临床试验行业的支柱。因此,开发具有成本效益的解决方案和减少药物开发过程中 CRO 的错误正在推动临床试验市场的增长。
欧洲临床试验市场已细分为英国、德国、法国、意大利、西班牙和欧洲其他地区。公司新药开发和创新产品推出的临床试验活动数量不断增加,可能会在预测期内促进欧洲市场的增长。
癌症、心血管疾病、神经系统疾病和传染病是德国临床试验中最常研究的疾病。临床研究受益于德国完善的交通、通讯、能源和公共服务基础设施,而且该国患者群体庞大,对优质医疗保健的需求很高。临床试验协调中心是联邦教育和研究部新资助计划的一部分,旨在促进学术临床研究。德国的临床试验由联邦药品和医疗器械研究所或保罗-埃利希研究所批准,具体取决于要研究的产品。因此,德国的临床试验审批流程标准化、可靠、透明,并且批准的研究启动时间相对较短。此外,德国顶级 CRO 提供多种临床试验服务。 Sofpromed 管理德国和其他欧盟成员国的临床试验。它为制药和生物技术公司提供全方位的CRO服务。同样,总部位于德国曼海姆的 CONET GmbH 提供从小型试点研究到所有阶段 (1–4) 的大型多中心国际临床试验的临床试验管理服务,包括根据欧盟指令的儿科临床试验和医疗器械试验。 span>
欧洲临床试验市场细分
欧洲临床试验市场分为阶段、研究设计、适应症和国家。
根据阶段,欧洲临床试验市场分为 I 期、II 期、III 期和第四阶段。到2022年,III期临床试验市场份额将成为欧洲最大的临床试验市场份额。
根据研究设计,欧洲临床试验市场分为介入性、观察性和扩大使用。到2022年,介入细分市场将占据欧洲最大的临床试验市场份额。
根据适应症,欧洲临床试验市场分为自身免疫/炎症、疼痛管理、肿瘤学、中枢神经系统状况、糖尿病、肥胖、心血管等。 2022 年,肿瘤学领域占据欧洲最大的临床试验市场份额。
按国家划分,欧洲临床试验市场分为英国、德国、法国、意大利、西班牙和欧洲其他地区。德国在 2022 年主导欧洲临床试验市场。
Charles River Laboratories International Inc、ICON Plc、IQVIA Holdings Inc、IXICO Plc、Laboratory Corp of America Holdings、Parexel International Corp、SGS SA、Syneos Health Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd. 是欧洲临床试验市场上的一些领先公司。
Strategic insights for Europe Clinical Trials involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 15,739.35 Million |
Market Size by 2028 | US$ 21,643.87 Million |
Global CAGR (2022 - 2028) | 5.5% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 研究设计
|
Regions and Countries Covered | 欧洲
|
Market leaders and key company profiles |
The regional scope of Europe Clinical Trials refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Clinical Trials Market is valued at US$ 15,739.35 Million in 2022, it is projected to reach US$ 21,643.87 Million by 2028.
As per our report Europe Clinical Trials Market, the market size is valued at US$ 15,739.35 Million in 2022, projecting it to reach US$ 21,643.87 Million by 2028. This translates to a CAGR of approximately 5.5% during the forecast period.
The Europe Clinical Trials Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Clinical Trials Market report:
The Europe Clinical Trials Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Clinical Trials Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Clinical Trials Market value chain can benefit from the information contained in a comprehensive market report.